Therapy Delayed is Therapy Denied: A Case Report of Melanoma Misdiagnosed as Diabetic Foot Ulcer

Abstract

Malignant melanoma is a deadly form of skin cancer, and prompt diagnosis is a key factor in providing adequate, life-saving therapy. A 75-year-old man, with long-standing type 2 diabetes mellitus, presented with a 2- to 3-year history of right heel ulcer. He had received various therapies for a diagnosis of diabetic foot ulcer, to no avail. Physical examination showed a black, fungating ulcerated lesion on his right heel, with minimal bleeding. No inguinal lymphadenopathy was palpated. A biopsy was done, which revealed BRAF-negative malignant melanoma, with a vertical growth phase, Breslow 3.1 mm, ulceration, 11 mitoses/mm², Clark level IV, no lymphatic or vascular invasion observed. Right inguinal lymph node sampling suggested no involvement, but PET-CT suggested pulmonary, right inguinal lymph node and bone involvement. The patient was referred to the oncologists. Written informed consent for publication was given by the patient. Diabetic foot ulcers are a frequently encountered, but serious complication of diabetes mellitus. Delayed healing is often seen, despite adequate therapy. The differential diagnosis of diabetic foot ulcers is vast and includes neoplasia. When a foot ulcer fails to heal, other differential diagnoses must be considered, in order for the patient to receive adequate therapy. Here specialist consultations, including dermatology consultations, could improve chances of delivering the right therapy promptly. This is a factor underlying the emphasis on a multidisciplinary approach to foot ulcer therapy. Our presentation – reported according to the CARE guidelines – also illustrates the fact that failure to reach a timely diagnosis may deny the patient the opportunity to receive adequate treatment. In such cases, “delayed therapy becomes denied (or failed) therapy”, paraphrasing the old adage “Justice delayed is justice denied”.

Keywords:

• malignant ulcer
• case report
• acral malignant melanoma
• diabetic foot ulcer
• type 2 diabetes mellitus
• delayed therapy

Introduction

Malignant melanoma is a lethal form of skin cancer. There are multiple therapeutic options for treating malignant melanoma. Surgery is preferred in the early stages and can be curative on its own. Patient education forms an essential part of preventive and therapeutic strategy, as many cases of malignant melanoma are discovered by the patients themselves. Failed therapy or delayed diagnosis can have unfortunate consequences. Diabetic foot ulcers (DFU) are a common, but serious, complication of diabetes with a worldwide prevalence of 6.3%¹ and a lifetime incidence of 25%.² Quite frequently patients fail to inform their doctors with regard to new lesions on their feet. Therefore, it is important for physicians to do a thorough examination of the feet, each time patients present, in order to more easily detect these lesions. Some 85% of non-traumatic lower extremity amputations occur in patients with diabetes.³ The differential diagnosis of DFU is vast and includes malignancy (squamous cell carcinoma, basal cell carcinoma, Kaposi sarcoma, malignant melanoma, Merkel cell carcinoma, Mycosis fungoides), infections (deep and superficial cutaneous mycosis, mycobacterial infections), necrobiosis lipoidica, pressure ulcers, vasculopathies (warfarin-induced necrosis, Factor V Leiden deficiency, cholesterol emboli, calciphylaxis), pyoderma gangrenosum, venous ulcers, hypertensive (Martorell) ulcers.⁴ Diabetes itself raises the risk for skin cancer.⁵ This raised risk is not just due to diabetes itself, which may be generating a locus minoris resistentiae,⁶ ie, an underlying tendency to cancer, as seen in other immune deficiency states,⁶ but this increased risk for skin cancer may be associated with medications often used to treat common comorbidities of diabetes, such as hydrochlorothiazide.^7,8 Some of the risk of the latter drug may be related to its potential phototoxicity.⁸ Without specialist, multidisciplinary input, which may help differentiate malignant from benign ulcers often by detecting subtle signs, these malignant ulcers may go undetected for long periods.⁹ Such cases are denied prompt and adequate therapy due to misdiagnosis or delayed diagnosis.

Case Presentation

A 75-year-old Caucasian male, with long-standing type 2 diabetes mellitus, presented with a 2- to 3-year history of painless, right heel ulcer. The ulcer had been growing gradually in size, despite adequate therapy. He had received various therapies for a diagnosis of diabetic foot ulcer, without experiencing significant improvement. Physical examination showed a black, fungating, ulcerated plaque covering his right heel, with a white fissure stretching from 12 o’clock to the middle of the lesion (Figure 1). There was minimal bleeding. No inguinal lymphadenopathy was palpated.

Figure 1 Melanoma of right heel. Right heel, with a black, well-defined plaque. There is evidence of bleeding and there is a white fissure stretching from 12 o’clock to the centre of the lesion.

A biopsy was done, which revealed BRAF-negative malignant melanoma, with a vertical growth phase, Breslow 3.1 mm, ulceration, 11 mitoses/mm,² Clark level IV, no lymphatic or vascular invasion observed. Right inguinal lymph node sampling suggested no involvement, but PET-computed tomography indicated pulmonary, right inguinal lymph node and bone involvement. A timeline detailing the various tests done is in Table 1.

Table 1 Timeline for Tests Done

Date	Event	Comments
16 Dec 2017	Initial patient visit, with biopsy for suspected acral melanoma right foot	18 Dec 2017, histopathology confirms acral lentiginous melanoma
08 Jan 2018	Whole-body CT	Numerous uncalcified micronodules in the lungs (5–8mm diameter)
18 Jan 2018	Lymphoscintigraphy	Multiple sentinel lymph nodes at right inguinal region
23 Jan 2018	Right inguinal node sampling	31 Jan 2018, rare, scattered tumour cells (HMB45, MelanA, PanMelanoma cocktail staining)
02 Mar 2018	Immunohistochemistry	Reactive adenopathy, no tumours
12 Apr 2018	Genetic testing	NO mutations in BRAF gene detected
18 Jul 2018	Whole-body PET-CT	Active areas at right heel, right inguinal area and lungs
18 Jan 2019	CT thorax and abdomen	Pulmonary nodules increased in size and number compared to previous year
23 Mar 2019	PET-CT	Progression of lesions with abdominal and thoracic lymph node involvement, as well as pulmonary and leg and foot bone involvement

The patient was referred to the oncologists.

Discussion

Acral lentiginous melanoma or acral melanoma was first described in 1977 by Arrington et al.¹⁰ It is the least common form of melanoma, accounting for 1–2% of cases¹¹ and has a lower survival rate than other forms of melanoma.¹¹ Therefore, timely diagnosis of this form of melanoma is critical to patient survival.

Acral lentiginous melanoma is often found on the areas of the foot prone to pressure and trauma, such as the heel, lateral aspect of the foot and the forefoot,¹⁰ which are also areas in which DFU commonly present. Confusion, leading to misdiagnosis, might cause delayed diagnosis and therefore a bleaker prognosis, as in this case. Our case presented with a heel ulcer of several years duration, which, due to its location and the patient’s underlying diabetes, was diagnosed and managed as a diabetic foot ulcer. Acral melanoma has also been misdiagnosed as interdigital tinea pedis,¹² illustrating the vastness of the differential diagnoses of DFU.^4,9,12 Failure to heal with worsening of the ulcer, despite treatment, did not appear to trigger earlier re-evaluation for a cutaneous malignancy or other differentials, perhaps because DFU are notoriously hard to heal. This difficulty in healing may be the reason why, even in a self-treating physician, melanoma was misdiagnosed and treated as a DFU.¹³

A referral for specialist (dermatology) care might have uncovered subtle signs that were easily missed at the primary care level. In many centres around the world, wound care is not often carried out by dermatologists, but by primary care staff, therefore such cases may “fall through the cracks”. Our study is limited by the fact that it is a case study and not a large review; however, the case itself is illustrative of why the differential diagnoses of DFU must always be considered in each patient and multidisciplinary teams are necessary for adequate DFU care.

Conclusion

DFU are a common, but serious complication of diabetes. As a result, the default diagnosis of ulcers on the feet of patients suffering from diabetes is often diabetic foot ulcer. Staff, who routinely care for patients with foot ulcers need to be aware of the other differential diagnoses of DFU, including malignancy and need to be prepared to promptly refer ulcers that are not responding to adequate care. It is also necessary for dermatologists to be more involved in the care of DFU as they are uniquely placed to recognise subtle, tell-tale signs that might point to a diagnosis such as this. In such cases, failure to achieve a prompt and accurate diagnosis could deny the patient prompt and adequate therapy.

Ethics and Consent

Written informed consent for the publication of this case was provided by the patient for the publication of photographs and all test results.

Institutional approval was not required as this is a case report and the patient had already given written informed consent for the publication of photographs and all test results.

Acknowledgments

The current work was academically supported by the ‘Dunarea de Jos’ University of Galati, Romania, through the research center – Multidisciplinary Integrated Center of Dermatological Interface Research (MIC-DIR).

Disclosure

The authors report no conflicts of interest in this work.

Additional information

Funding

This work was supported by the “Dunarea de Jos” University of Galati, Romania.